This sex-specific efficacy of anti–PD-1 was unclear, since previous studies on the role of obesity in the response to immunotherapy typically used only one sex (9, 13) or rarely performed sex-based analyses (9, 36). The gene discussed is PDCD1; the disease is obesity due to melanocortin 4 receptor deficiency.